
WilmerHale Advises Argos Therapeutics in Pricing of \$50M Public Offering

JULY 28, 2016

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the pricing of its public offering of \$50 million.

The WilmerHale team was led by Partner [Stuart Falber](#) and included Associate Leora Rodenstein, Senior Associate [Ryan Mitteness](#), Associate [Andrea Sorrentino](#), Attorney [Heidi Treiber](#) and Senior Associate Mia Kelley. Partner [Julie Hogan Rodgers](#) and Associate [Leah Segal](#) (Tax) were also involved.

Read [Argos Therapeutics' press release](#) for more information.